SCHEMBL960819

SCHEMBL960819

O=C(O)CC(O)(C(F)(F)F)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 3/20 0.48
ALDH1A1 P00352 1/20 0.46
HMGCR P04035 1/20 0.46
CHRM1 P11229 1/20 0.46
TBXA2R P21731 1/20 0.46
ADRA1A P35348 1/20 0.46
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HTT P42858 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
TET2 Q6N021 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
HIF1A Q16665 1/20 0.38
CPT2 P23786 1/20 0.36
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
HSP90AA1 P07900 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2947382 0.79 KMT2A (0.39) ACLYALDH1A1MEN1KMT2AHTT
SCHEMBL8466961 0.77 ACLY (0.48) ACLYALDH1A1HMGCRCHRM1TBXA2R
SCHEMBL11509869 0.77 HMGCR (0.52) ACLYALDH1A1HMGCRCHRM1TBXA2R
SCHEMBL24380150 0.76 HMGCR (0.58) ACLYALDH1A1HMGCRCHRM1TBXA2R
SCHEMBL5605062 0.74 KMT2A (0.41) ACLYALDH1A1HMGCRCHRM1TBXA2R
SCHEMBL13560384 0.74 KMT2A (0.41) ACLYALDH1A1MEN1KMT2AHTT
SCHEMBL14556955 0.74 TET2 (0.63) ACLYMEN1KMT2AHTTNPSR1
SCHEMBL865358 0.73 ACLY (0.44) ACLYALDH1A1HMGCRCHRM1TBXA2R
SCHEMBL28358175 0.73 ACLY (0.44) ACLYALDH1A1HMGCRCHRM1TBXA2R
SCHEMBL4643961 0.73 ACLY (0.44) ACLYALDH1A1HMGCRCHRM1TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030199687-A1 Biocompatible materials and probes CARBOMER, INC. 2003-10-23 US claimed
WO-2003087165-A2 BIOCOMPATIBLE MATERIALS AND PROBES CARBOMER, INC. (US) 2003-10-23 WO claimed
US-20030194378-A1 Novel aerosol formulation containing a polar fluorinated molecule ASTRAZENECA AB (SE) 2003-10-16 US claimed
EP-1303258-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE AstraZeneca AB (SE) 2003-04-23 EP claimed
WO-2002003958-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE ASTRAZENECA AB (SE) 2002-01-17 WO claimed
US-12508239-B2 Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures H. LUNDBECK A/S (DK) 2025-12-30 US disclosed
EP-4007571-B1 ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES H LUNDBECK AS (DK) 2025-06-18 EP disclosed
EP-4241843-B1 ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS H LUNDBECK AS (DK) 2025-05-21 EP disclosed
US-20250110101-A1 PER AND POLYFLUOROALKYL SUBSTANCE MEASUREMENT DEXSIL CORPORATION (US) 2025-04-03 US disclosed
US-12258305-B2 Alcohol derivatives as Kv7 potassium channel openers H. LUNDBECK A/S (DK) 2025-03-25 US disclosed
US-20240059860-A1 METHODS AND SYSTEMS FOR DESTRUCTION OF SYNTHETIC PER- AND POLYFLUORO COMPOUNDS CHZ TECHNOLOGIES, LLC 2024-02-22 US disclosed
US-20240027902-A1 CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-01-25 US disclosed
US-6485868-B1 Electrolyte for electrochemical device CENTRAL GLASS COMPANY, LIMITED (JP) 2002-11-26 US disclosed
US-6407232-B1 BATTERIES, CAPACITORS, POLYMERIZATION CATALYST CENTRAL GLASS COMPANY, LIMITED (JP) 2002-06-18 US disclosed
WO-2002003958-A1 NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE ASTRAZENECA AB (SE) 2002-01-17 WO disclosed
EP-1075036-A2 Electrolyte for electrochemical device Central Glass Company, Limited (JP) 2001-02-07 EP disclosed
EP-1074555-A2 Ionic metal complex and process for synthesizing same Central Glass Company, Limited (JP) 2001-02-07 EP disclosed
US-6043385-A TREATMENT OF PSORIASIS, BASAL CELL CARCINOMAS, DISORDERS OF KERATINIZATION AND KERATOSIS, NEOPLASTIC DISEASES SUCH AS LEUKEMIA, DISORDERS OF THE SEBACEOUS GLANDS SUCH AS ACNE AND SEBORRHOIC DERMATITIS, OSTEOPOROSIS, HYPERPARATHYROIDISM HOFFMAN-LA ROCHE INC. (US) 2000-03-28 US disclosed
WO-1999031055-A1 NOVEL VITAMIN D3 AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1999-06-24 WO disclosed
US-4069273-A Dimerization of linear alpha-olefins CHEVRON RESEARCH COMPANY (US) 1978-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12508239-B2 Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures KCNN3, KCNN1, KCNN2 ACLY 3490/4885ALDH1A1 763/4885HMGCR 3031/4885
US-12258305-B2 Alcohol derivatives as Kv7 potassium channel openers KCNA7, KCNK17, KCNQ1 ACLY 2850/4885ALDH1A1 633/4885HMGCR 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.